RESUMEN
A series of selenium-containing miconazole derivatives were identified as potent antifungal drugs in our previous study. Representative compound A03 (MIC = 0.01 µg/mL against C.alb. 5314) proved efficacious in inhibiting the growth of fungal pathogens. However, further study showed lead compound A03 exhibited potential hemolysis, significant cytotoxic effect and unfavorable metabolic stability and was therefore modified to overcome these drawbacks. In this article, the further optimization of selenium-containing miconazole derivatives resulted in the discovery of similarly potent compound B17 (MIC = 0.02 µg/mL against C.alb. 5314), exhibiting a superior pharmacological profile with decreased rate of metabolism, cytotoxic effect and hemolysis. Furthermore, compound B17 showed fungicidal activity against Candida albicans and significant effects on the treatment of resistant Candida albicans infections. Meanwhile, compound B17 not only could reduce the ergosterol biosynthesis pathway by inhibiting CYP51, but also inhibited biofilm formation. More importantly, compound B17 also shows promising in vivo efficacy after intraperitoneal injection and the PK study of compound B17 was evaluated. In addition, molecular docking studies provide a model for the interaction between the compound B17 and the CYP51 protein. Overall, we believe that these selenium-containing miconazole compounds can be further developed for the potential treatment of fungal infections.
Asunto(s)
Inhibidores de 14 alfa Desmetilasa/química , Antifúngicos/química , Miconazol/química , Selenio/química , Esterol 14-Desmetilasa/química , Inhibidores de 14 alfa Desmetilasa/metabolismo , Inhibidores de 14 alfa Desmetilasa/farmacología , Inhibidores de 14 alfa Desmetilasa/uso terapéutico , Animales , Antifúngicos/metabolismo , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Sitios de Unión , Biopelículas/efectos de los fármacos , Candida/efectos de los fármacos , Candida/fisiología , Candidiasis/tratamiento farmacológico , Candidiasis/patología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Modelos Animales de Enfermedad , Diseño de Fármacos , Semivida , Humanos , Ratones , Miconazol/metabolismo , Miconazol/farmacología , Miconazol/uso terapéutico , Pruebas de Sensibilidad Microbiana , Simulación del Acoplamiento Molecular , Esterol 14-Desmetilasa/metabolismo , Relación Estructura-ActividadRESUMEN
Vulvovaginal candidiasis (VVC) is caused mainly by the opportunistic fungus Candida albicans, and its yeast to hyphae transition is considered a major virulence factor. Farnesol is a molecule that inhibits yeast to hyphae transition. The increased incidence of VVC has influenced a need for developing new therapeutic strategies. The objective was to develop a mucoadhesive nanostructured system composed of miconazole and farnesol co-encapsulated within chitosan nanoparticles. The miconazole presented a minimal inhibitory concentration (MIC) of 1 µg/ml against C. albicans. The farnesol was capable of inhibiting yeast to hyphae transition at levels greater or equal to 300 µM. The combination of miconazole and farnesol showed no change in miconazole MIC. Chitosan nanoparticles containing miconazole and farnesol were prepared by ionic gelation and showed favorable characteristics for use on mucous membranes. They showed size variation and polydispersion index (PDI) after 30 days, but the efficiency of drug encapsulation was maintained. Regarding toxicity in cultured fibroblasts (BALB/c 3T3) the nanoparticles were considered nontoxic. The nanoparticles showed antifungal activity against the C. albicans strain used with MICs of 2.5 µg/ml and 2 µg/ml for nanoparticles containing miconazole or miconazole/farnesol, respectively. Nanoparticles containing farnesol inhibited yeast to hyphae transition at concentrations greater than or equal to 240 µM. The in vivo antifungal activity was assessed in the murine model for VVC. The results suggested that chitosan nanoparticles containing miconazole and farnesol were effective at inhibiting fungal proliferation. Additionally, chitosan nanoparticles containing farnesol were capable of decreasing the pathogenicity of infection, demonstrated through the absence of inflammation.
Asunto(s)
Candida albicans/efectos de los fármacos , Candidiasis Vulvovaginal/tratamiento farmacológico , Farnesol , Miconazol , Nanopartículas/química , Animales , Antifúngicos/síntesis química , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Células 3T3 BALB , Candida albicans/crecimiento & desarrollo , Candidiasis Vulvovaginal/patología , Cápsulas , Quitosano/química , Modelos Animales de Enfermedad , Farnesol/química , Farnesol/farmacología , Farnesol/uso terapéutico , Femenino , Ratones , Ratones Endogámicos BALB C , Miconazol/química , Miconazol/farmacología , Miconazol/uso terapéutico , Pruebas de Sensibilidad Microbiana , Viabilidad Microbiana/efectos de los fármacos , Nanopartículas/uso terapéuticoRESUMEN
In this work, chitosan films were prepared by a casting/solvent evaporation methodology using pectin or hydroxypropylmethyl cellulose to form polymeric matrices. Miconazole nitrate, as a model drug, was loaded into such formulations. These polymeric films were characterized in terms of mechanical properties, adhesiveness, and swelling as well as drug release. Besides, the morphology of raw materials and films was investigated by scanning electron microscopy; interactions between polymers were analyzed by infrared spectroscopy and drug crystallinity studied by differential scanning calorimetry and X-ray diffraction. In addition, antifungal activity against cultures of the five most important fungal opportunistic pathogens belonging to Candida genus was investigated. Chitosan:hydroxypropylmethyl cellulose films were found to be the most appropriate formulations in terms of folding endurance, mechanical properties, and adhesiveness. Also, an improvement in the dissolution rate of miconazole nitrate from the films up to 90% compared to the non-loaded drug was observed. The in vitro antifungal activity showed a significant activity of the model drug when it is loaded into chitosan films. These findings suggest that chitosan-based films are a promising approach to deliver miconazole nitrate for the treatment of candidiasis.
Asunto(s)
Candidiasis Bucal/tratamiento farmacológico , Quitosano , Sistemas de Liberación de Medicamentos , Derivados de la Hipromelosa/farmacología , Miconazol , Adhesividad , Administración Bucal , Antidiarreicos/química , Antidiarreicos/farmacología , Antifúngicos/química , Antifúngicos/farmacología , Quitosano/química , Quitosano/farmacología , Composición de Medicamentos , Humanos , Miconazol/química , Miconazol/farmacología , Microscopía Electrónica de Rastreo/métodos , Pectinas/química , Pectinas/farmacología , Polímeros/farmacología , Difracción de Rayos X/métodosRESUMEN
Azoles are among the most successful classes of antifungals. They act by inhibiting α-14 lanosterol demethylase in the ergosterol biosynthesis pathway. Oropharyngeal candidiasis (OPC) occurs in about 90% of HIV-infected individuals, and 4 to 5% are refractory to current therapies, including azoles, due to the formation of resistant biofilms produced in the course of OPC. We reasoned that compounds affecting a different target may potentiate azoles to produce increased killing and an antibiofilm therapeutic. 2-Adamantanamine (AC17) was identified in a screen for compounds potentiating the action of miconazole against biofilms of Candida albicans. AC17, a close structural analog to the antiviral amantadine, did not affect the viability of C. albicans but caused the normally fungistatic azoles to become fungicidal. Transcriptome analysis of cells treated with AC17 revealed that the ergosterol and filamentation pathways were affected. Indeed, cells exposed to AC17 had decreased ergosterol contents and were unable to invade agar. In vivo, the combination of AC17 and fluconazole produced a significant reduction in fungal tissue burden in a guinea pig model of cutaneous candidiasis, while each treatment alone did not have a significant effect. The combination of fluconazole and AC17 also showed improved efficacy (P value of 0.018) compared to fluconazole alone when fungal lesions were evaluated. AC17 is a promising lead in the search for more effective antifungal therapeutics.
Asunto(s)
Amantadina/análogos & derivados , Antifúngicos/farmacología , Miconazol/farmacología , Amantadina/farmacología , Animales , Antifúngicos/química , Biopelículas/efectos de los fármacos , Candida albicans/química , Candida albicans/efectos de los fármacos , Candida albicans/genética , Candidiasis Cutánea/tratamiento farmacológico , Medios de Cultivo/química , Evaluación Preclínica de Medicamentos , Sinergismo Farmacológico , Ergosterol/metabolismo , Fluconazol/farmacología , Perfilación de la Expresión Génica , Cobayas , Células Hep G2 , Hepatocitos/microbiología , Humanos , Miconazol/químicaRESUMEN
Residue of azole antifungals in the environment is of concern due to the environmental risks and persistence. Distribution, behavior, and fate of frequently used azole antifungal pharmaceuticals were investigated in wastewater at two sewage treatment plants (STPs) in China. Fluconazole, clotrimazole, econazole, ketoconazole, and miconazole were constantly detected at 1-1834 ng L(-1) in the wastewater. The latter four were also ubiquitously detected in sewage sludge. Fluconazole passed through treatment in the STPs and largely remained in the final effluent. On the contrary, biotransformation and sorption to sludge occurred to the other azoles. Ketoconazole was more readily bio-transformed, whereas clotrimazole, econazole, and miconazole were more likely to be adsorbed onto and persisted in sewage sludge. Lipophilicity plays the governing role on adsorption. The highest concentrations in the raw wastewater were observed in winter for the azole pharmaceuticals except for fluconazole. The seasonal difference was smoothed out after treatment in the STPs.
Asunto(s)
Antifúngicos/análisis , Azoles/análisis , Eliminación de Residuos Líquidos/métodos , Contaminantes Químicos del Agua/análisis , Antifúngicos/química , Azoles/química , Biodegradación Ambiental , China , Clotrimazol/análisis , Clotrimazol/química , Econazol/análisis , Econazol/química , Monitoreo del Ambiente , Fluconazol/análisis , Fluconazol/química , Cetoconazol/análisis , Cetoconazol/química , Miconazol/análisis , Miconazol/química , Aguas del Alcantarillado/química , Contaminantes Químicos del Agua/químicaRESUMEN
Concentrations of six pharmaceutical antimycotics were determined in the sewage water, final effluent and sludge of five Swedish sewage treatment plants (STPs) by solid phase extraction, liquid/solid extraction, and liquid chromatography-electrospray tandem mass spectrometry. The antimycotics were quantified by internal standard calibration. The results were used to estimate national flows that were compared to predictions based on sales figures. Fluconazole was the only one of the six investigated antimycotics that was detected (at concentrations ranging from 90 to 140 ng L(-1)) in both raw sewage water and final effluent. Negligible amounts of this substance were removed from the aqueous phase, and its levels were below the limit of quantification in all of the analyzed sludge samples. In contrast, clotrimazole, ketoconazole and econazole were present in all of the sludge samples, at concentrations ranging between 200 and 1000 microg kg(-1), dry weight. There were close correlations between the national measured and predicted antimycotic mass flows. Antimycotic fate analysis, based on sales figures, indicated that 53% of the total amount of fluconazole sold appeared in the final effluents of the STPs, while 1, 155, 35, 209 and 41% of the terbinafine, clotrimazole, ketoconazole, econazole and miconazole sold appeared in the digested dewatered sludge.
Asunto(s)
Antifúngicos/análisis , Aguas del Alcantarillado/química , Contaminantes Químicos del Agua/análisis , Antifúngicos/química , Clotrimazol/análisis , Clotrimazol/química , Econazol/análisis , Econazol/química , Monitoreo del Ambiente , Fluconazol/análisis , Fluconazol/química , Cetoconazol/análisis , Cetoconazol/química , Miconazol/análisis , Miconazol/química , Naftalenos/análisis , Naftalenos/química , Suecia , Terbinafina , Eliminación de Residuos Líquidos , Contaminantes Químicos del Agua/químicaRESUMEN
The feasibility of using collagen as the base of miconazole was investigated. The addition of 33% collagen to a miconazole solution did not affect the minimal inhibitory concentration (MIC80) of the miconazole solution for Candida albicans. When 1 microg mL(-1) of miconazole in 33% collagen solution was plated on resin discs and dried to yield a thin membrane, the growth of C. albicans on the resin discs was nearly completely inhibited. In addition, we compared the antifungal effect of this collagen solution that contained 1 microg mL(-1) miconazole, with the antifungal effect of miconazole gel that had been diluted with glycerol (the main component of miconazole gel) to yield a final concentration of 1 microg mL(-1) of miconazole; as a result, we found that the collagen solution containing 1 microg mL(-1) miconazole had a stronger antifungal effect. In conclusion, our results demonstrated that it may be feasible to use collagen as the base of miconazole instead of glycerol, and suggest that a collagen-based miconazole solution would have a stronger antifungal effect than commercially available miconazole gel. Collagen-based miconazole solution may be useful for the treatment of Candida-associated denture stomatitis.
Asunto(s)
Antifúngicos/farmacología , Candida albicans/efectos de los fármacos , Colágeno/farmacología , Portadores de Fármacos/farmacología , Miconazol/farmacología , Antifúngicos/química , Candida albicans/crecimiento & desarrollo , Recuento de Colonia Microbiana , Evaluación Preclínica de Medicamentos , Estudios de Factibilidad , Humanos , Miconazol/química , Pruebas de Sensibilidad Microbiana/métodosRESUMEN
The objective of this investigation was to evaluate an acetic acid ester of monoglycerides made from edible, fully hydrogenated palm oil (AC-70) as a suppository base and compare it with a commercially available semisynthetic base (Suppocire AI). Benzocaine and miconazole were used as model drugs. Suppositories were prepared by the fusion method. The drug loads in the suppositories were kept at 2% to 5% (wt/wt). In vitro release of drug from the suppositories into Sorensen's phosphate buffer (pH 7.4) was studied using a US Pharmacopeia dissolution apparatus 1 and a spectrophotometer. The melting behavior of the bases and the physical state of the drug in the suppositories were studied using a differential scanning calorimeter (DSC). Powder x-ray diffractometry was used to study any possible polymorphic changes in the AC-70 base during formulation and storage. In vitro release studies revealed that the release of benzocaine from the AC-70 suppository was substantially slower than that of the commercial AI base. At a 2.5% (wt/wt) benzocaine load, the release of drug from the AC-70 suppositories was found to be linear. This slow and linear release was attributed to the physical property of the base, which forms liquid crystalline phases in the aqueous dissolution medium. The lyotropic liquid crystalline phase has the ability to incorporate drug into its structure and can control the release kinetics of the drug from such a system. The apparent pH of the release medium (water) was decreased by 1 to 1.5 pH units when the AC-70 base was used. The DSC studies revealed that the melting range of the AC-70 base is 36 degrees C to 38 degrees C, which is ideal for suppository formulations. The results of these studies support the possibility of using this new base for slow-release suppository formulations. This base may be of particular interest for a drug that requires an acidic environment to maintain its activity.